US2022118087A1PendingUtilityA1
Methods for treating gi syndrome and graft versus host disease
Assignee: SLOAN KETTERING INST CANCER RESPriority: May 25, 2012Filed: Jul 17, 2020Published: Apr 21, 2022
Est. expiryMay 25, 2032(~5.8 yrs left)· nominal 20-yr term from priority
A61K 45/06C07K 2317/24A61K 31/496A61K 39/39533A61K 31/4709C07K 2317/76A61P 1/00A61K 31/55A61P 39/00C07K 16/44A61K 39/39541A61P 43/00C07K 16/18
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.
Claims
exact text as granted — not AI-modified1 .- 9 . (canceled)
10 . An anti-ceramide antibody or antigen-binding fragment thereof, comprising a variable heavy chain (VH) and a variable light chain (VL),
wherein the VH comprises a VH-CDR1 sequence of NYWMH, a VH-CDR2 sequence of AIYPGDSDTSYNQKFKG, and a VH-CDR3 sequence of LYYGYD, and wherein the VL comprises a VL-CDR1 sequence of KSSQSLIDSDGKTFLNW, a VL-CDR2 sequence of LVSKLDS, and a VL-CDR3 sequence of WQGTHFPYT; wherein the VH comprises
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGA
IYPGDSDTSYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLY
YGYDWGQGTTVTVSS.
11 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , wherein the VL comprises
DVVMTQSPLSLPVTLGQPASISCKSSQSLIDSDGKTFLNWFQQRPGQSPR
RLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFP
YTFGQGTKLEIK.
12 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , wherein the antibody is an IgG antibody.
13 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 12 , wherein the antibody is an IgG1 antibody.
14 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , wherein the antibody is an IgM antibody.
15 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , wherein the antigen-binding fragment is a scFv.
16 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , comprising a heavy chain comprising
QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYWMHWVRQAPGQGLEWMGA
IYPGDSDTSYNQKFKGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARLY
YGYDWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE
PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNV
NHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM
ISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLP
PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG
SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG.
17 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , comprising a light chain comprising
DVVMTQSPLSLPVTLGQPASISCKSSQSLIDSDGKTFLNWFQQRPGQSPR
RLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFP
YTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAK
VQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACE
VTHQGLSSPVTKSFNRGEC.
18 . The anti-ceramide antibody or antigen-binding fragment thereof according to claim 10 , comprising a heavy chain according to SEQ ID NO: 6.
19 . The anti-ceramide antibody according to claim 10 , comprising a light chain according to SEQ ID NO: 8.
20 . An anti-ceramide antibody or antigen-binding fragment thereof, comprising a variable heavy chain (VH) and a variable light chain (VL),
wherein the VH comprises a VH-CDR1 sequence of NYWMH, a VH-CDR2 sequence of AIYPGDSDTSYNQKFKG, and a VH-CDR3 sequence of LYYGYD, and wherein the VL comprises a VL-CDR1 sequence of KSSQSLIDSDGKTFLNW, a VL-CDR2 sequence of LVSKLDS, and a VL-CDR3 sequence of WQGTHFPYT; wherein the VL comprises
DVVMTQSPLSLPVTLGQPASISCKSSQSLIDSDGKTFLNMTQQRPGQSPR
RLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCWQGTHFP
YTFGQGTKLEIK.Join the waitlist — get patent alerts
Track US2022118087A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.